Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Expression of activator protein-1 (AP-1) family members in breast cancer

Authors: Amirhossein Kharman-Biz, Hui Gao, Reza Ghiasvand, Chunyan Zhao, Kazem Zendehdel, Karin Dahlman-Wright

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer.

Methods

We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student’s t-test, one-way ANOVA, logistic regression and Pearson’s correlation coefficient for statistical analyses.

Results

We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01).

Conclusions

Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Canc J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Canc J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef
2.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa women's health study: how many kinds of breast cancer are there?. Canc Epidemiol Biomarkers Prev. 1995, 4 (4): 319-326. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa women's health study: how many kinds of breast cancer are there?. Canc Epidemiol Biomarkers Prev. 1995, 4 (4): 319-326.
6.
go back to reference Weigel MT, Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Canc. 2010, 17 (4): R245-R262. 10.1677/ERC-10-0136.CrossRef Weigel MT, Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Canc. 2010, 17 (4): R245-R262. 10.1677/ERC-10-0136.CrossRef
7.
go back to reference Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Canc. 2002, 2 (2): 101-112. 10.1038/nrc721.CrossRef Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Canc. 2002, 2 (2): 101-112. 10.1038/nrc721.CrossRef
8.
go back to reference Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15 (1): 17-35.PubMed Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15 (1): 17-35.PubMed
9.
go back to reference Huang W-Y, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. Am J Epidemiol. 2000, 151 (7): 703-714. 10.1093/oxfordjournals.aje.a010265.CrossRefPubMed Huang W-Y, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. Am J Epidemiol. 2000, 151 (7): 703-714. 10.1093/oxfordjournals.aje.a010265.CrossRefPubMed
10.
go back to reference Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA: International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006, 58 (4): 773-781. 10.1124/pr.58.4.8.CrossRefPubMed Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA: International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006, 58 (4): 773-781. 10.1124/pr.58.4.8.CrossRefPubMed
11.
go back to reference Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000, 74 (5): 311-317. 10.1016/S0960-0760(00)00108-4.CrossRefPubMed Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000, 74 (5): 311-317. 10.1016/S0960-0760(00)00108-4.CrossRefPubMed
12.
go back to reference Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Loning T, Bamberger AM: The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Canc Res Treat. 2004, 86 (2): 139-152. 10.1023/B:BREA.0000032982.49024.71.CrossRef Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Loning T, Bamberger AM: The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Canc Res Treat. 2004, 86 (2): 139-152. 10.1023/B:BREA.0000032982.49024.71.CrossRef
13.
go back to reference Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991, 1072 (2–3): 129-157.PubMed Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991, 1072 (2–3): 129-157.PubMed
14.
go back to reference Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Canc. 1999, 84 (5): 533-538. 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J.CrossRef Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Canc. 1999, 84 (5): 533-538. 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J.CrossRef
15.
go back to reference Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M: Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol. 2006, 27 (4): 345-352.PubMed Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M: Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol. 2006, 27 (4): 345-352.PubMed
16.
go back to reference Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger AM, Janicke F, Loning T: Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Canc Res Treat. 2008, 107 (3): 337-347. 10.1007/s10549-007-9559-y.CrossRef Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger AM, Janicke F, Loning T: Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Canc Res Treat. 2008, 107 (3): 337-347. 10.1007/s10549-007-9559-y.CrossRef
17.
go back to reference Logullo AF, Stiepcich MM, Osorio CA, Nonogaki S, Pasini FS, Rocha RM, Soares FA, Brentani MM: Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011, 58 (4): 617-625. 10.1111/j.1365-2559.2011.03785.x.CrossRefPubMedPubMedCentral Logullo AF, Stiepcich MM, Osorio CA, Nonogaki S, Pasini FS, Rocha RM, Soares FA, Brentani MM: Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011, 58 (4): 617-625. 10.1111/j.1365-2559.2011.03785.x.CrossRefPubMedPubMedCentral
18.
go back to reference Schroder C, Schumacher U, Muller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K: The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Canc. 2010, 46 (9): 1650-1660. 10.1016/j.ejca.2010.02.008.CrossRef Schroder C, Schumacher U, Muller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K: The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Canc. 2010, 46 (9): 1650-1660. 10.1016/j.ejca.2010.02.008.CrossRef
19.
go back to reference LaValley MP: Logistic regression. Circulation. 2008, 117 (18): 2395-2399. 10.1161/CIRCULATIONAHA.106.682658.CrossRefPubMed LaValley MP: Logistic regression. Circulation. 2008, 117 (18): 2395-2399. 10.1161/CIRCULATIONAHA.106.682658.CrossRefPubMed
20.
go back to reference O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clin Canc Res. 2010, 16 (24): 6100-6110. 10.1158/1078-0432.CCR-10-1533.CrossRef O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clin Canc Res. 2010, 16 (24): 6100-6110. 10.1158/1078-0432.CCR-10-1533.CrossRef
21.
go back to reference El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI: Effects of young age at presentation on survival in breast cancer. BMC Canc. 2006, 6: 194-10.1186/1471-2407-6-194.CrossRef El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI: Effects of young age at presentation on survival in breast cancer. BMC Canc. 2006, 6: 194-10.1186/1471-2407-6-194.CrossRef
22.
go back to reference Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A: Delayed presentation in breast cancer: a study in Iranian women. BMC Women's Health. 2003, 3 (1): 4-10.1186/1472-6874-3-4.CrossRefPubMedPubMedCentral Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A: Delayed presentation in breast cancer: a study in Iranian women. BMC Women's Health. 2003, 3 (1): 4-10.1186/1472-6874-3-4.CrossRefPubMedPubMedCentral
23.
go back to reference Mousavi M, Montazeri A, Mohagheghi MA, Mousavi Jarrahi A, Harirchi I, Najafi M, Ebrahimi M: Breast Cancer in Iran: An Epidemiological Review. Breast J. 2007, 13 (4): 383-391. 10.1111/j.1524-4741.2007.00446.x.CrossRefPubMed Mousavi M, Montazeri A, Mohagheghi MA, Mousavi Jarrahi A, Harirchi I, Najafi M, Ebrahimi M: Breast Cancer in Iran: An Epidemiological Review. Breast J. 2007, 13 (4): 383-391. 10.1111/j.1524-4741.2007.00446.x.CrossRefPubMed
24.
go back to reference Mousavi SM, Zheng T, Dastgiri S, Miller AB: Age distribution of breast cancer in the middle East, implications for screening. Breast J. 2009, 15 (6): 677-679. 10.1111/j.1524-4741.2009.00843.x.CrossRefPubMed Mousavi SM, Zheng T, Dastgiri S, Miller AB: Age distribution of breast cancer in the middle East, implications for screening. Breast J. 2009, 15 (6): 677-679. 10.1111/j.1524-4741.2009.00843.x.CrossRefPubMed
25.
go back to reference Smith LM, Birrer MJ, Stampfer MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Canc Res. 1997, 57 (14): 3046-3054. Smith LM, Birrer MJ, Stampfer MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Canc Res. 1997, 57 (14): 3046-3054.
26.
go back to reference Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, Vuttariello E, Arnaldi L, Di Bonito M, D'Aiuto G, Pierantoni GM, et al: FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Canc. 2007, 7: 17-10.1186/1471-2407-7-17.CrossRef Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, Vuttariello E, Arnaldi L, Di Bonito M, D'Aiuto G, Pierantoni GM, et al: FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Canc. 2007, 7: 17-10.1186/1471-2407-7-17.CrossRef
27.
go back to reference Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D: The PKCtheta pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 2012, 31 (47): 4889-4897. 10.1038/onc.2011.659.CrossRefPubMedPubMedCentral Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D: The PKCtheta pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 2012, 31 (47): 4889-4897. 10.1038/onc.2011.659.CrossRefPubMedPubMedCentral
28.
go back to reference Belguise K, Kersual N, Galtier F, Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005, 24 (8): 1434-1444. 10.1038/sj.onc.1208312.CrossRefPubMed Belguise K, Kersual N, Galtier F, Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005, 24 (8): 1434-1444. 10.1038/sj.onc.1208312.CrossRefPubMed
29.
go back to reference Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM: FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Canc Res Treat. 2003, 77 (3): 265-275. 10.1023/A:1021887100216.CrossRef Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM: FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Canc Res Treat. 2003, 77 (3): 265-275. 10.1023/A:1021887100216.CrossRef
Metadata
Title
Expression of activator protein-1 (AP-1) family members in breast cancer
Authors
Amirhossein Kharman-Biz
Hui Gao
Reza Ghiasvand
Chunyan Zhao
Kazem Zendehdel
Karin Dahlman-Wright
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-441

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine